Why Lichen Sclerosus Flares Come Back (Even When You're Doing Everything Right)

April 16, 2026

By

Alex Cuggiani

LS doesn't come back randomly. Five biological loops are running beneath the surface, and addressing one while the others run is enough to restart the whole system. This is the loop architecture, why trigger avoidance alone fails, and what management at the loop level actually means.

Lichen sclerosus flare triggers and immune activation in skin

There is a question that arrives for almost every patient who has lived with lichen sclerosus for more than a year. Why does it keep coming back? Why does a period of good control, where treatment is working and symptoms have quieted, give way to another flare? Why does reducing treatment reliably produce symptoms even in patients who have been stable for months? Why does the same trigger keep initiating the same cycle?

The standard answer, that LS is a chronic autoimmune condition and relapse is expected, offers no framework for understanding why relapses follow the patterns they do, no explanation for why some patients cycle far faster than others, and no basis for management decisions beyond treating flares as they arrive.

The more accurate answer is this: lichen sclerosus does not come back randomly. It comes back because biological loops are running continuously beneath the visible surface of the disease, loops that sustain each other through their interactions, and that require more than the interruption of any single one of them to stop.

What a Flare Actually Is, Biologically

Before examining why flares return, it helps to be precise about what a flare represents at the biological level. A flare is not simply the presence of itch or burning. Biologically, it represents the re-activation of local immune signaling, increased release of inflammatory cytokines including interferon-gamma, TNF-alpha, and IL-1beta in the affected tissue, renewed disruption of the epidermal barrier, and re-sensitization of local nerve fibers. What makes this clinically important is that the inflammatory cascade can be running before the skin shows any visible change. This is why flares so often feel confusing, appearing without redness, bleeding, or obvious lesions. The tissue is reacting before the damage is visible, and the immune environment is already shifted before symptoms reach the level patients recognize as a flare.

The other critical point is that once this cascade is reactivated, the skin does not simply need a large or obvious trigger to sustain it. It needs only enough combined input across multiple biological pathways to keep the system above its activation threshold. Understanding that threshold, and what keeps it low, is the key to understanding why flares return.

From Processes to Loops: How LS Sustains Itself

LS involves three broad biological processes: inflammation, barrier disruption, and fibrotic remodeling. What makes the disease chronic rather than episodic is not simply that these processes exist. It is that they are connected in a way that allows each one to restart the others when they have been temporarily quieted.

When the inflammation loop is suppressed by treatment, the barrier loop may continue generating immune activation through mechanical micro-injury. When the barrier loop is addressed, the neuroimmune loop may sustain itch through pathways that cytokine suppression cannot reach. When inflammation and barrier are both managed, the fibrosis loop may advance quietly on its own slower timeline. And operating across all of them, the trigger amplification loop progressively lowers the threshold at which any of the others can be restarted.

This is the loop architecture of LS: five distinct feedback loops, connected in ways that give the disease its most frustrating clinical feature. The disease is able to re-establish itself from multiple directions simultaneously, from biological activity running quietly beneath any level of management that addresses only one of its components.

The Five Loops

Loop 1: The Inflammation Loop

Immune cells release inflammatory cytokines, which recruit additional immune cells, which release more cytokines. The loop amplifies itself without requiring a new external trigger at each step. The previous step generates the conditions for the next. Anti-inflammatory treatment interrupts this loop effectively. The problem is not that the treatment fails to interrupt it. The problem is that interrupting the inflammation loop does not prevent the other four loops from restarting it. Each time pharmacological suppression is reduced without the other loops having been addressed, the inflammation loop is re-fed from the mechanical, neuroimmune, and fibrotic sides.

Loop 2: The Barrier Damage Loop

Inflammation disrupts the epidermal barrier by depleting ceramides and compromising the integrity of the stratum corneum. A disrupted barrier allows ordinary daily mechanical activities, including clothing friction, movement, exercise, and repeated wiping, to generate micro-injuries that reach the immune-reactive tissue beneath. Each micro-injury activates keratinocytes, which release danger signals and stimulate cytokine release, sustaining and amplifying the inflammation loop. The barrier loop operates independently of the primary autoimmune process. It requires only a sufficiently disrupted barrier and ordinary daily life to continue running. An unrecovered barrier restarts the inflammation loop from the mechanical side even when pharmacological suppression has been successful, which is why symptom recurrence after stopping steroids is so reliably observed.

Loop 3: The Neuroimmune Itch Loop

IL-31 and mast cell mediators sensitize C-fibers, the peripheral nerve endings involved in itch signaling. Sensitized nerves fire at lower thresholds, generating itch disproportionate to the inflammatory stimulus present. Scratching in response to this itch produces mechanical barrier disruption that feeds back into the barrier loop and the inflammation loop. The neuroimmune loop can run semi-independently once nerve sensitization is established, generating itch through a pathway that cytokine suppression does not directly address. This is why persistent itch after a successful steroid course is not evidence of treatment failure. The inflammation loop has been quieted. The sensitized nerve fibers have not been reset, and they continue firing at thresholds the inflammation loop no longer needs to maintain.

Loop 4: The Fibrosis Loop

Tissue injury from inflammation, mechanical micro-trauma, and barrier disruption activates TGF-beta and IL-13 signaling, instructing fibroblasts to deposit collagen. When this signaling is sustained chronically, collagen accumulates and tissue becomes progressively stiffer. Stiffer tissue is more vulnerable to micro-tears from normal movement, and those micro-tears generate injury signals that continue feeding the fibrotic pathway. The fibrosis loop does not require dramatic inflammatory activity to advance. It needs only the low-level, continuous mechanical and inflammatory activation that the other loops provide. Fibrotic changes accumulate even in patients with apparently well-managed inflammation, because the fibrosis loop is being fed by loop activity below the clinical threshold of the inflammation loop, but above zero. Progressive tightness and pallor in a patient who reports feeling stable is often this loop advancing unnoticed.

Loop 5: The Trigger Amplification Loop

This loop is less a discrete biological cascade than an emergent property of the first four operating together over time. As each loop runs, it contributes to a general lowering of the tissue's activation threshold. The immune environment becomes sensitized. The barrier becomes chronically more permeable. The nerve fibers become constitutively more reactive. The fibroblasts respond to progressively smaller injury signals. The combined effect is a tissue environment that has become increasingly ready to respond, one where stimuli that would have passed without consequence earlier in the disease course now reliably cross the threshold required to activate one or more of the other loops. The trigger is never the whole story. The terrain that made the trigger effective is the story. Reducing trigger exposure helps, but it does not restore the terrain. Only reducing loop activity does that.

Why Addressing One Loop Is Not Enough

The loop architecture explains the relapse patterns most patients recognize. Anti-inflammatory treatment interrupts the inflammation loop effectively. But if the barrier loop is running simultaneously, the inflammation loop will be reestablished as soon as pharmacological suppression is reduced. If the neuroimmune loop is active, scratching continues producing barrier disruption and immune reactivation through a pathway that cytokine suppression does not reach. If the fibrosis loop has been advancing quietly, the tissue's mechanical vulnerability has increased, making reactivation from barrier micro-injury easier with each cycle.

Each loop left running while another is addressed represents a pathway through which the addressed loop will be restarted. The system does not need all five loops simultaneously active at high levels. It needs only enough combined loop activity to exceed the activation threshold, a threshold the trigger amplification loop has been progressively lowering.

Durable stability requires reducing activity across multiple loops simultaneously. Not necessarily with a different treatment for each, but with management broad enough that no single loop's continued activity is sufficient to restart the system. This is the biological explanation for why patients who do everything their clinician prescribes, who are fully compliant with steroid treatment and complete every course, still experience progressive shortening of flare-free intervals. The prescription addressed the inflammation loop. The barrier loop, the neuroimmune loop, and the fibrosis loop were left running. Each incomplete cycle accumulated activity in the other loops, lowering the activation threshold until ordinary life became a sufficient trigger.

Mechanical Triggers and the Two-Day Delay

Mechanical stress is one of the strongest drivers of LS flares and one of the least discussed, partly because the timing obscures the connection. LS tissue develops microscopic injury more easily than healthy tissue because barrier depletion and fibrotic changes both reduce mechanical resilience. When micro-injuries occur, whether from clothing friction, exercise, sexual activity, or prolonged sitting, the immune response they trigger does not appear immediately. The two-day delay mechanism means that mechanical micro-injury produces immune activation approximately 12 to 48 hours after the event. This delay is why patients so often cannot identify what caused a flare. The friction that activated the barrier and inflammation loops happened yesterday or the day before, not this morning.

This timing has practical implications. A friction event on a Wednesday produces symptoms on Thursday or Friday. The patient reviews Thursday and Friday looking for a cause and finds nothing. The correct window is Tuesday and Wednesday. Once this delay is understood, many flares that felt random begin to map cleanly onto preceding mechanical events. The management implication follows: barrier reinforcement before anticipated friction events is more useful than escalated anti-inflammatory treatment after symptoms have already arrived.

Barrier Breakdown: Why Protection Matters Immunologically

A compromised barrier makes LS flares more likely not because of comfort or moisture alone, but because of what barrier failure means for immune activation. When the stratum corneum is intact, external mechanical inputs are buffered before they reach immune-reactive tissue. When ceramide depletion and ongoing inflammation have compromised that layer, the same mechanical inputs reach immune tissue directly and generate the danger signals that restart the inflammation loop.

This is why daily barrier protection is not a cosmetic consideration. It is an immune-relevant intervention that directly reduces the rate of input into the barrier damage loop. Products such as petrolatum, Cicalfate, Cicaplast Baume B5+, and VEA Lipogel do not treat the underlying disease, but they reduce the frequency at which ordinary daily activity crosses the micro-injury threshold. In patients with significantly disrupted barrier function, this reduction can be the difference between a management approach that holds and one that keeps failing despite correct anti-inflammatory treatment.

The barrier loop also explains why flares so reliably return after stopping steroids when nothing else has changed. The steroid suppressed the inflammation loop, but the barrier that was disrupted by that inflammation has not fully recovered. Ordinary friction resumes. Micro-injuries occur. The inflammation loop is re-fed from the barrier side within days. The patient concludes the steroid stopped working. The steroid worked correctly. The barrier was never addressed.

Infection, Dysbiosis, and Misread Flares

LS is not caused by infection, but microbial imbalance can trigger immune activation that is clinically indistinguishable from a primary LS flare. Yeast overgrowth, bacterial dysbiosis, and prolonged moisture and occlusion all generate inflammatory signals that feed into the same pathways driving the LS inflammation loop. Steroids suppress the immune response to these signals but do not resolve their source. When infection or dysbiosis is present, steroid treatment temporarily masks symptoms while the trigger continues running. This is a common pattern in flares that seem partially responsive to treatment, improve somewhat with steroid use, but never fully resolve and return quickly when the steroid is stopped. The relevant question in these cases is not whether to use more steroid but whether the input driving the inflammation loop is immunological, mechanical, or microbial, because each requires a different response.

Stress, Hormonal Shifts, and the Neuroimmune Pathway

Psychological stress does not cause LS, but it modulates it through mechanisms that are biological rather than incidental. Stress activates the sympathetic nervous system, produces cortisol fluctuations, and drives neuroimmune signaling in the skin. These effects lower the threshold at which triggers cause flares. Under heightened neuroimmune activation, friction is experienced more intensely, burning is amplified, and recovery from barrier disruption takes longer. The neuroimmune loop is directly influenced by systemic stress state, which is why stress-related flares are biological events with predictable mechanistic causes rather than psychological responses to a difficult period.

Hormonal factors operate through a related mechanism. During menopause, hormonal shifts, illness, and other systemic inflammatory states, skin resilience decreases, immune balance shifts, and the tissue's susceptibility to triggers increases. Estrogen deprivation in particular contributes to a form of atrophy distinct from fibrotic atrophy, reducing the tissue's mechanical tolerance and making the barrier more vulnerable to disruption. These hormonal effects do not cause LS, but they influence how readily the loops already running can be restarted by inputs that would previously have been sub-threshold.

Why Flares Feel Unpredictable: The Stacking Effect

Most flares are not caused by a single factor. The stacking effect describes what happens when multiple sub-threshold inputs arrive close together. Mild friction alone does not cross the activation threshold. A somewhat weakened barrier alone does not cross it. A stressful week alone does not cross it. But mild friction combined with a weakened barrier combined with elevated stress, arriving within the same 48-hour window, produces combined input sufficient to restart the system. None of the individual factors seemed significant. None would have been worth flagging on their own. Together they crossed the threshold that restarts inflammation.

This stacking dynamic is why flares feel random until you look back across the preceding 48 hours with the full loop architecture in mind. The trigger was not a single dramatic event. It was ordinary life combining at a moment when the terrain was reactive enough that ordinary life was sufficient. The trigger amplification loop makes this more likely over time by continuing to lower the activation threshold, so the number of factors required to stack into a flare decreases as the disease progresses without loop reduction. A patient who needed three factors stacking to flare in year one may need only one by year four, not because the disease has changed categorically but because the terrain has been progressively sensitized.

The Trigger Identification Trap

Recognizing that specific events reliably precede flares is valuable. Many patients identify friction events, particular foods, stressful periods, or product changes as consistent precursors to flares, and avoiding those triggers reduces their frequency. This matters and the work of identifying patterns is worth doing.

The problem arises when trigger avoidance substitutes for loop reduction as the primary management strategy. The trigger amplification loop means that reducing trigger exposure does not reduce the threshold at which activation occurs. A patient who avoids every identified trigger while leaving underlying loop activity unaddressed will eventually find that new triggers emerge. She has not resolved the problem. She has only raised the bar slightly. The sensitized terrain continues lowering the activation threshold, and eventually ordinary life itself becomes sufficient to cross it regardless of how carefully known triggers are managed.

Clinical example: the patient who ran out of things to avoid. A patient has systematically identified and eliminated triggers over three years: friction from cycling, certain foods, fragranced laundry products, stress during work periods, tight clothing. Each elimination reduced flare frequency for a period, but flares continued to return with new triggers she had not identified before. She concludes the disease is unpredictable and uncontrollable. The trigger amplification loop framework gives a different reading. She has been managing at the trigger level while the loops running beneath continued to lower her activation threshold. Each new trigger that emerged was not a new disease driver. It was a previously sub-threshold stimulus now crossing a threshold that had been lowered by continued loop activity. The correct redirected question is not "what trigger am I missing?" It is: which loops are still running, and what is keeping them active? Barrier integrity, nerve sensitization level, fibrotic progression, maintenance medication frequency. Addressing those reduces the terrain reactivity that is making ordinary stimuli effective triggers.

The goal is not to eliminate triggers. The goal is to restore the terrain to a state where ordinary life does not constitute a trigger. That requires addressing the loops that are keeping the terrain reactive, not the external stimuli that are exploiting the terrain's reactivity.

What This Means for Management

The loop model gives patients a diagnostic framework for relapse that replaces the undifferentiated response of "my disease is back" with a structured question: which loop restarted the system, and at which entry point?

A symptom spike appearing 24 to 48 hours after a friction event is a barrier loop entry. The response it calls for is barrier reinforcement before the next friction event, not escalated anti-inflammatory treatment after symptoms have arrived. A gradual symptom increase over weeks with no obvious trigger is the inflammation loop reestablishing through immune memory, calling for maintenance medication review and trigger assessment. Itch that persists after inflammation has been controlled is the neuroimmune loop continuing to run through sensitized C-fibers that cytokine suppression does not directly reach. Progressive tightness and pallor in the absence of active inflammatory symptoms is the fibrosis loop advancing on its own slower timeline, calling for antifibrotic monitoring rather than steroid escalation. A disproportionate response to a minor trigger that previously caused no problem is the trigger amplification loop signaling that the terrain has become more reactive, that the threshold has been lowered, and that the real target is the combined loop activity keeping the terrain sensitized rather than the specific trigger that happened to cross it this time.

Each entry point suggests a different management priority. Identifying the entry point changes the response from generic escalation to targeted interruption. The same management tool applied to different entry points will not produce the same result, and applying more of a tool that targets only one loop while others continue running will not produce durable stability.

Frequently Asked Questions

Why does my LS come back even when I use the steroid correctly?

Because the steroid addresses one loop, the inflammation loop, precisely and effectively. It does not address the barrier loop, the neuroimmune loop, or the fibrosis loop, which continue running after the inflammatory signal has been suppressed. When suppression is reduced, these other loops provide enough input to restart the inflammation loop. The drug is doing its job correctly. The management framework around it is incomplete if nothing is being done about the other loops during the interval between courses. Barrier care, maintenance medication frequency, and attention to nerve sensitization all represent loop reduction strategies that change what happens when the anti-inflammatory course ends.

My flares seem to come out of nowhere without any obvious trigger. Why?

When the trigger amplification loop has significantly lowered the activation threshold, stimuli that previously did not constitute triggers become sufficient to initiate a cascade. The trigger was present, perhaps friction from dressing in the morning, a mild hormonal fluctuation, or a brief stressful period, but it fell below the level you would recognize as significant. The disease did not come from nowhere. The terrain had become reactive enough that something you would not have noticed triggered it. The relevant question is not what the trigger was. The relevant question is why the threshold was low enough for that stimulus to cross it, which points back to which loops are still running beneath the visible surface of the disease.

I've eliminated all my known triggers but still get flares. What am I missing?

The trigger amplification loop. Reducing trigger exposure lowers the number of inputs crossing the activation threshold, which reduces flare frequency. But it does not lower the threshold itself. The threshold is determined by the combined activity of the other four loops. As long as those loops continue running, the threshold continues falling, and eventually stimuli too small to identify or eliminate emerge as effective triggers. The redirected question is not "what trigger am I missing?" but "which loops are still running and what is keeping them active?" Barrier integrity, maintenance medication adherence, nerve sensitization state, and fibrotic progression are the places to look.

Does understanding the loop model actually change what I should do?

Yes, specifically. Instead of treating each flare as an isolated event requiring the same response, meaning more anti-inflammatory treatment, the loop model directs attention to which entry point is currently most active and whether the management response is actually reaching it. Post-friction symptom spikes require barrier reinforcement, not escalated steroids. Persistent itch after inflammation control requires neuroimmune-targeted management, not more cytokine suppression. Progressive structural changes in apparently stable periods require antifibrotic monitoring. Daily barrier care and maintenance medication are loop reduction strategies, not passive precautions, and understanding them as such changes how consistently they are maintained. The model makes management decisions mechanistically grounded rather than reactive, which is the difference between managing at the trigger level and actually restoring the terrain.

‍

Content sourced from: Lichen Sclerosus Decoded, A New Way to Understand and Manage Lichen Sclerosus. For informational purposes only. This article does not constitute medical advice. Please consult a qualified healthcare provider for diagnosis and treatment.

Scientific References: Why Lichen Sclerosus Flares Keep Coming Back

Book by Alex Force

Lichen Sclerosus Decoded: A New Way to Understand and Manage Lichen Sclerosus

The phase-based framework that explains why symptoms change, why treatments sometimes stop working, and what you can actually do about it. Written for patients who want to understand the biology, not just follow instructions.

Read on Amazon →

Credits

Alex Cuggiani

→

Website Owner

In the same category

All

/

Featured Blogs

/